Nilotinib is a tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML). It works by blocking the BCR-ABL fusion protein, inhibiting cancer cell proliferation. Nilotinib is effective in managing specific blood cancers. In summary, Nilotinib is vital for treating CML.
Nilotinib inhibits BCR-ABL tyrosine kinase activity, blocking the signaling pathways that promote cancer cell growth.